HROW Harrow Health Inc.

Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference

Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference

NASHVILLE, Tenn., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in H.C. Wainwright’s 5th Annual Ophthalmology Conference on Wednesday, August 13, 2025, being held virtually.

Harrow’s Chief Executive Officer, Mark L. Baum, and Chief Financial Officer, Andrew Boll, will participate in a fireside chat on Wednesday, August 13 at 8:30 a.m. Eastern time. In addition, Mark will participate in a panel discussion on “Novel Treatments for Front-of-the-Eye Indications” at 1 p.m. Eastern time.

Both the and the will be webcast live and can be found on the Company’s website. A replay will be on the website for approximately 90 days following the event.

About Harrow

Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its portfolio of pharmaceutical products accessible and affordable to millions of patients each year. For more information about Harrow, please visit .

Contact:

Mike Biega, Vice President of Investor Relations and Communications



617-913-8890



EN
06/08/2025

Underlying

HROWHarrow Health Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Harrow Health Inc.

 PRESS RELEASE
Free
HROW Harrow Health I...

Harrow to Present at Two Investor Conferences in December

Harrow to Present at Two Investor Conferences in December NASHVILLE, Tenn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will participate in the following two investor conferences in December: BTIG 5th Annual Ophthalmology Day (Virtual)Format: Fireside chatDate/Time: Monday, December 1, 2025, at 8:30 AM EST Piper Sandler 37th Annual Healthcare Conference (New York, NY)Format: Fireside chatDate/Time: Tuesday, December 2, 2025, at 3:00 PM EST The fireside chat at Pi...

November 24, 2025 1 EN
 PRESS RELEASE
Free
HROW Harrow Health I...

Harrow Announces Closing of Acquisition of Melt Pharmaceuticals

Harrow Announces Closing of Acquisition of Melt Pharmaceuticals NASHVILLE, Tenn., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the acquisition of Melt Pharmaceuticals, Inc. (Melt), a clinical-stage pharmaceutical company pioneering non-opioid, non-IV therapies for sedation for medical procedures in the hospital, outpatient, and in-office settings. Melt’s product candidates, MELT-210, MELT-300, and MELT-400, are based on the proprietary Zydis® ODT (oral dissolvi...

November 18, 2025 1 EN
 PRESS RELEASE
Free
HROW Harrow Health I...

Harrow Announces Third Quarter 2025 Financial Results

Harrow Announces Third Quarter 2025 Financial Results Third-Quarter 2025 and Recent Selected Highlights:  Total revenues of $71.6 million, a 45% increase over $49.3 million recorded in the prior-year periodGAAP net income of $1.0 millionAdjusted EBITDA of $22.7 millionCash and cash equivalents of $74.3 million as of September 30, 2025 NASHVILLE, Tenn., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, announced results for the third quarter ended September 30, 2025. The Company also posted its thi...

November 10, 2025 1 EN
 PRESS RELEASE
Free
HROW Harrow Health I...

Harrow To Report Third Quarter 2025 Financial Results After Market Clo...

Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025 Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on November 11, 2025 NASHVILLE, Tenn., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the third quarter ended September 30, 2025, on Monday, November 10, 2025, after the market close. The Company will also post its third quarter Letter to Stockholders to the “Investors”...

October 27, 2025 1 EN
 PRESS RELEASE
Free
HROW Harrow Health I...

ImprimisRx Announces Leadership Changes

ImprimisRx Announces Leadership Changes Frank Mullery Appointed Chief Executive Officer of ImprimisRx Bridseida Cruz Appointed Head of Quality of ImprimisRx NASHVILLE, Tenn., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced leadership changes at its wholly-owned subsidiary, ImprimisRx. Frank Mullery has been appointed as Chief Executive Officer and Bridseida Cruz has been appointed as Head of Quality of ImprimisRx. Mr. Mullery is a senior executive with over 20 years of leadership ex...

October 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch